Propranolol (inderal) in Persistent Ventricular Fibrillation.

Acute and chronic effects of an adrenergic beta-receptor blocking agent (propranolol) in treatment of cardiac arrhythmias.

THE INTRODUCTION of the adrenergic beta-receptor blocking agent, pronethalol,1 and the more recent availability of its analogue propranolol2 have served as a new impetus in the pharmacological study of the cardiovascular system. Clinical use of these compounds has been explored in the treatment of hypertension,3 angina pectoris,4 prolonged systemic hypotension,5 hypertrophic subaortic stenosis,...

The effect of propranolol on left ventricular function at rest and during exercise in patients with ischemic heart disease.

Twelve patients with ischemic heart disease were investigated by right and left heart catheterisation. All patients were studied at rest and during exercise, both before and after administration of beta-blocker propranolol, Inderal (ICI). Left ventricular function decreased after administration of propranolol, but these changes were significant only during exercise. Contractility was depressed ...

Propranolol (inderal) in Disturbances of Cardiac Rhythm.

Double-blind Trial of Propranolol (inderal) in Angina Pectoris.

Beta-adrenergic blockade and cardiac arrhythmias.

The evaluation of beta-adrenergic blockade in cardiac arrhythmias is difficult because of the complex nature of the arrhythmias and the varied modes of action of blocking drugs. Studies have confirmed the therapeutic value of the betaadrenergic blocking drug pronethalol (Alderlin) (Vaughan Williams, 1963 ; Stock and Dale, 1963 ; Payne and Senfield, 1964; Wolfson et al., 1966) and its more poten...